Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Prediction Markets
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
  • WIIM
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
17 minute read
  • Earnings

Earnings Scheduled For February 23, 2023

By Benzinga Insights
Today, 3:20 AM
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

AAOI

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

MannKind’s Inhaled Clofazimine Will Advance To An Adaptive Phase 2/3 Study For Potential Treatment Of Rare Lung Disease

By Benzinga Newsdesk
Today, 3:20 AM
Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side effects Paper published on

MNKD

Read More
1 minute read
  • Analyst Ratings
  • Markets
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Price Target
  • Small Cap
  • Trading Ideas

MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday

By Lisa Levin
Today, 3:20 AM
SVB Leerink raised MannKind Corporation (NASDAQ:MNKD) price target from $5 to $6. . SVB Leerink analyst Thomas Smith…

CARG

Read More
21 minute read
  • Earnings

Earnings Scheduled For November 8, 2022

By Benzinga Insights
Today, 3:20 AM
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.

ABCL

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Penny Stocks
  • Small Cap

MannKind Shares Fall After Completing Initial Stage Lung Disease Study

By Ragothaman Srinivasan
Today, 3:20 AM
MannKind Corporation (NASDAQ: MNKD) has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101), an inhalation treatment option for nontuberculous mycobacterial (NTM) lung disease.

MNKD

Read More
3 minute read
  • Biotech
  • General

Mannkind Completes Phase 1 Study of Inhaled Clofazimine; Says ‘Study supports the dosing regimen that will be pursued in further clinical programs’

By Bill Haddad
Today, 3:20 AM
  Study supports the dosing regimen that will be pursued in further clinical programs No serious adverse events or QT prolongation identified Planning underway to discuss results and the ongoing clinical

MNKD

Read More
22 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For August 9, 2022

By Benzinga Insights
Today, 3:20 AM
  Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

AAIC

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

UPDATE: FDA Doc For United Therapeutics, MannKind Lung Disease Therapy (Link In Body Of This Headline)

By Benzinga Newsdesk
Today, 3:20 AM
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214324s000lbl.pdf

MNKD

Read More
4 minute read
  • Biotech
  • Earnings
  • FDA
  • General
  • Health Care
  • Large Cap
  • Legal
  • Management
  • News
  • Penny Stocks
  • Small Cap

The Daily Biotech Pulse: Pfizer-BioNTech’s COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio’s AP-013 Trial Under Independent Investigation

By Vandana Singh
Today, 3:20 AM
Here's a roundup of top developments in the biotech space over the last 24 hours:

ABEO

Read More
1 minute read
  • Earnings
  • News

MannKind Q1 EPS $(0.10), Inline, Sales $11.99M Beat $10.58M Estimate

By Benzinga Newsdesk
Today, 3:20 AM
MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 100 percent decrease over losses of $(0.05) per share from the same period last year. The company

MNKD

Posts navigation

1 2 … 8 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service